US · SRPT
Sarepta Therapeutics, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Cambridge, MA 02142
- Website
- sarepta.com
Price · as of 2024-12-31
$21.49
Market cap 1.76B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $138.52 | +544.58% |
| Intrinsic Value(DCF) | $43.32 | +101.58% |
| Graham-Dodd Method(GD) | $28.44 | +32.34% |
| Graham Formula(GF) | $145.55 | +577.29% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | $11.40 | $32.54 | $453.56 | $0.00 | $0.00 |
| 2011 | $6.42 | $32.36 | $1,301.23 | $0.90 | $0.00 |
| 2012 | $30.43 | $177.17 | $13.30 | $0.00 | $59.49 |
| 2013 | $27.59 | $30.76 | $4.19 | $0.00 | $169.39 |
| 2014 | $14.11 | $18.58 | $2.18 | $0.00 | $74.31 |
| 2015 | $15.74 | $24.53 | $0.00 | $0.00 | $391.66 |
| 2016 | $32.63 | $47.02 | $0.93 | $0.00 | $0.00 |
| 2017 | $74.36 | $435.52 | $5,711.44 | $9.11 | $0.00 |
| 2018 | $130.80 | $64.36 | $521,172.80 | $0.00 | $0.00 |
| 2019 | $117.10 | $51.12 | $8,489.85 | $0.00 | $0.00 |
| 2020 | $86.47 | $60.57 | $3,885.43 | $0.00 | $0.00 |
| 2021 | $77.85 | $120.01 | $1,288.71 | $0.00 | $0.00 |
| 2022 | $143.92 | $69.40 | $396.49 | $0.00 | $0.00 |
| 2023 | $124.37 | $56.95 | $817.41 | $0.00 | $0.00 |
| 2024 | $103.03 | $138.52 | $944.27 | $28.44 | $145.55 |
AI valuation
Our deep-learning model estimates Sarepta Therapeutics, Inc.'s (SRPT) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $138.52
- Current price
- $21.49
- AI upside
- +544.58%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$43.32
+101.58% upside
Graham-Dodd
$28.44
+32.34% upside
Graham Formula
$145.55
+577.29% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| SRPT | Sarepta Therapeutics, Inc… | $21.49 | 1.76B | +545% | +102% | +32% | +577% | 41.64 | 6.41 | 5.15 | 30.87 | — | 6.53 | 83.22% | 11.47% | 12.37% | 19.71% | 18.77% | 6.51% | 0.88 | 11.86 | 4.20 | 2.74 | 0.76 | -14034.00% | 5297.00% | -4004.00% | -3.60% | -0.28 | -33.66% | 0.00% | 0.00% | 7.44% | 44.86 | -27.74 | 5.14 | 2.30 |
| ADPT | Adaptive Biotechnologies … | $16.02 | 2.46B | +132% | +239% | — | — | -41.11 | 11.18 | 8.83 | -83.74 | — | 24.93 | 74.24% | -20.62% | -21.48% | -28.23% | -33.39% | -11.31% | 1.28 | -4.85 | 3.34 | 3.08 | -7.04 | -6389.00% | 5477.00% | -5050.00% | -2.00% | -0.51 | -28.61% | 0.00% | 0.00% | 0.00% | -43.75 | -51.06 | 9.02 | 2.04 |
| AGIO | Agios Pharmaceuticals, In… | $30.23 | 1.77B | -31% | +212% | — | — | -4.10 | 1.42 | 31.33 | -1.93 | — | 1.42 | 88.26% | -873.87% | -764.01% | -30.20% | -85.25% | -27.89% | 0.05 | — | 11.46 | 10.52 | 0.06 | -16117.00% | 4803.00% | -364.00% | -22.29% | -4.54 | -68.29% | 0.00% | 0.00% | 0.46% | -1.91 | -2.39 | 16.67 | 8.79 |
| BEAM | Beam Therapeutics Inc. | $28.46 | 2.89B | +40% | +284% | -70% | — | -35.47 | 2.29 | 20.31 | -63.04 | — | 2.29 | 84.05% | -274.57% | -57.24% | -8.11% | -231.66% | -6.19% | 0.24 | -8.77 | 13.09 | 12.85 | 0.04 | -8231.00% | 12001.00% | 108.00% | -12.69% | -3.56 | -217.38% | 0.00% | 0.00% | 0.00% | -4.92 | -5.24 | 13.50 | 5.65 |
| COGT | Cogent Biosciences, Inc. | $38.85 | 6.31B | — | — | — | — | -7.99 | 4.13 | — | -6.03 | -218.46 | 4.13 | 0.00% | — | — | -73.70% | 2714.02% | -51.99% | 0.40 | -108.87 | 14.23 | 14.08 | 0.18 | 366.00% | — | 2766.00% | -10.12% | -4.13 | 2165.58% | 0.00% | 0.00% | 0.00% | -5.94 | -7.45 | — | 3.37 |
| DNLI | Denali Therapeutics Inc. | $21.18 | 3.31B | — | — | — | — | -7.19 | 3.63 | — | -5.73 | -46.19 | 3.63 | 0.00% | — | — | -45.69% | -177.80% | -40.69% | 0.03 | — | 9.16 | 8.82 | 0.35 | 1556.00% | — | 1609.00% | -11.46% | -4.20 | -135.14% | 0.00% | 0.00% | 1.26% | -5.13 | -6.75 | — | 13.60 |
| IBRX | ImmunityBio, Inc. | $9.78 | 9.63B | +901% | -57% | — | — | — | -19.22 | 84.77 | -45.80 | — | -18.70 | 99.34% | -226.00% | -310.18% | 0.00% | -52123.97% | 0.00% | -1.76 | -2.28 | 5.10 | 4.62 | -3.53 | -3871.00% | 66831.00% | -2341.00% | -3.18% | -4.94 | -62105.09% | 0.00% | — | 0.00% | -39.99 | -33.58 | 90.38 | -5.49 |
| MLYS | Mineralys Therapeutics, I… | $29.26 | 1.94B | — | — | — | — | -2.87 | 2.67 | — | -1.62 | -3.42 | 2.67 | 0.00% | — | — | -82.24% | 16423.64% | -77.72% | 0.00 | — | 14.02 | 13.53 | 0.59 | 8392.00% | — | 10501.00% | -32.59% | -11.36 | 14204.87% | 0.00% | 0.00% | 12.69% | -1.62 | -1.88 | — | 16.89 |
| RCUS | Arcus Biosciences, Inc. | $20.37 | 2.05B | +8% | -43% | — | — | -7.28 | 4.07 | 10.41 | -5.04 | -152.47 | 4.07 | 95.95% | -156.28% | -142.91% | -63.26% | 112.87% | -30.84% | 0.16 | -48.25 | 4.36 | 4.25 | 0.37 | 478.00% | -426.00% | 17500.00% | -18.82% | -2.09 | 141.52% | 0.00% | 0.00% | 1.28% | -4.38 | -3.49 | 6.84 | 1.13 |
| RXRX | Recursion Pharmaceuticals… | $3.67 | 1.47B | +586% | +721% | — | — | -2.52 | 1.44 | 21.75 | -1.71 | — | 2.47 | -61.96% | -867.87% | -863.35% | -59.54% | -127.75% | -44.12% | 0.07 | -358.08 | 5.50 | 5.20 | 1.19 | -1479.00% | 2692.00% | 145.00% | -23.29% | -2.52 | -74.58% | 0.00% | 0.00% | 11.05% | -1.48 | -2.53 | 12.84 | 0.01 |
About Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
- CEO
- Douglas S. Ingram
- Employees
- 1.37K
- Beta
- 0.39
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($43.32 ÷ $21.49) − 1 = +101.58% (DCF, example).